nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—HIF1A—gall bladder—bile duct cancer	0.0408	0.128	CbGeAlD
Carvedilol—NPPB—pancreas—bile duct cancer	0.0315	0.0983	CbGeAlD
Carvedilol—VCAM1—pancreas—bile duct cancer	0.0195	0.0611	CbGeAlD
Carvedilol—HIF1A—pancreas—bile duct cancer	0.0188	0.0588	CbGeAlD
Carvedilol—GJA1—pancreas—bile duct cancer	0.0182	0.057	CbGeAlD
Carvedilol—VEGFA—pancreas—bile duct cancer	0.0144	0.045	CbGeAlD
Carvedilol—SELE—liver—bile duct cancer	0.0135	0.0423	CbGeAlD
Carvedilol—VCAM1—liver—bile duct cancer	0.0124	0.0389	CbGeAlD
Carvedilol—HIF1A—liver—bile duct cancer	0.012	0.0374	CbGeAlD
Carvedilol—GJA1—liver—bile duct cancer	0.0116	0.0363	CbGeAlD
Carvedilol—SELE—lymph node—bile duct cancer	0.0104	0.0324	CbGeAlD
Carvedilol—NDUFC2—liver—bile duct cancer	0.0101	0.0316	CbGeAlD
Carvedilol—VCAM1—lymph node—bile duct cancer	0.00954	0.0298	CbGeAlD
Carvedilol—HIF1A—lymph node—bile duct cancer	0.00917	0.0287	CbGeAlD
Carvedilol—VEGFA—liver—bile duct cancer	0.00916	0.0287	CbGeAlD
Carvedilol—GJA1—lymph node—bile duct cancer	0.0089	0.0278	CbGeAlD
Carvedilol—XDH—liver—bile duct cancer	0.00816	0.0255	CbGeAlD
Carvedilol—NDUFC2—lymph node—bile duct cancer	0.00775	0.0242	CbGeAlD
Carvedilol—VEGFA—lymph node—bile duct cancer	0.00703	0.022	CbGeAlD
Carvedilol—ADRA2C—pancreas—bile duct cancer	0.00515	0.0161	CbGeAlD
Carvedilol—ADRA2A—pancreas—bile duct cancer	0.00411	0.0128	CbGeAlD
Carvedilol—ADRA1A—liver—bile duct cancer	0.00344	0.0108	CbGeAlD
Carvedilol—ADRA2C—liver—bile duct cancer	0.00328	0.0102	CbGeAlD
Carvedilol—CYP1A2—liver—bile duct cancer	0.00284	0.00889	CbGeAlD
Carvedilol—CYP1A1—liver—bile duct cancer	0.0028	0.00877	CbGeAlD
Carvedilol—CYP2C9—liver—bile duct cancer	0.0027	0.00844	CbGeAlD
Carvedilol—CYP2E1—liver—bile duct cancer	0.00256	0.008	CbGeAlD
Carvedilol—KCNH2—lymph node—bile duct cancer	0.00255	0.00796	CbGeAlD
Carvedilol—ADRA2C—lymph node—bile duct cancer	0.00251	0.00785	CbGeAlD
Carvedilol—ABCB1—pancreas—bile duct cancer	0.00229	0.00716	CbGeAlD
Carvedilol—CYP1A1—lymph node—bile duct cancer	0.00215	0.00672	CbGeAlD
Carvedilol—CYP3A4—liver—bile duct cancer	0.00206	0.00643	CbGeAlD
Carvedilol—CYP2D6—liver—bile duct cancer	0.00203	0.00633	CbGeAlD
Carvedilol—ADRA2A—lymph node—bile duct cancer	0.002	0.00627	CbGeAlD
Carvedilol—PTGS1—lymph node—bile duct cancer	0.00189	0.00591	CbGeAlD
Carvedilol—ABCB1—liver—bile duct cancer	0.00146	0.00455	CbGeAlD
Carvedilol—ABCB1—lymph node—bile duct cancer	0.00112	0.00349	CbGeAlD
Carvedilol—VEGFA—Signaling Pathways—SMAD4—bile duct cancer	0.000218	0.000321	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—bile duct cancer	0.000215	0.000317	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—NRAS—bile duct cancer	0.000215	0.000317	CbGpPWpGaD
Carvedilol—HIF1A—Disease—IL6—bile duct cancer	0.000215	0.000316	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—NOS2—bile duct cancer	0.000214	0.000315	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—IDH1—bile duct cancer	0.000213	0.000313	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—TP53—bile duct cancer	0.00021	0.000308	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—GNAS—bile duct cancer	0.000207	0.000305	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—bile duct cancer	0.000206	0.000303	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—HRAS—bile duct cancer	0.000204	0.0003	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—GNAS—bile duct cancer	0.000204	0.0003	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—IDH1—bile duct cancer	0.000201	0.000295	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—HRAS—bile duct cancer	0.0002	0.000295	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—TGFB1—bile duct cancer	0.0002	0.000294	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—GNAS—bile duct cancer	0.000199	0.000293	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—EGFR—bile duct cancer	0.000196	0.000288	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—IL6—bile duct cancer	0.000196	0.000288	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—bile duct cancer	0.000191	0.000281	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—SLC5A5—bile duct cancer	0.000188	0.000277	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—SLC5A5—bile duct cancer	0.000188	0.000276	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—IDH2—bile duct cancer	0.000187	0.000274	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—GNAS—bile duct cancer	0.000185	0.000272	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—KRAS—bile duct cancer	0.000185	0.000272	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—bile duct cancer	0.000183	0.000269	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—GNAS—bile duct cancer	0.000181	0.000266	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.000176	0.000259	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—IDH2—bile duct cancer	0.000176	0.000258	CbGpPWpGaD
Carvedilol—ABCB1—Transmembrane transport of small molecules—GNAS—bile duct cancer	0.000176	0.000258	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—IDH2—bile duct cancer	0.000174	0.000256	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	0.000172	0.000252	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.000168	0.000247	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—GNAS—bile duct cancer	0.000168	0.000247	CbGpPWpGaD
Carvedilol—XDH—Metabolism—PTGS2—bile duct cancer	0.000168	0.000246	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—TP53—bile duct cancer	0.000165	0.000242	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—NRAS—bile duct cancer	0.000162	0.000237	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—IDH1—bile duct cancer	0.00016	0.000236	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.000159	0.000234	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—NRAS—bile duct cancer	0.000158	0.000232	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—HRAS—bile duct cancer	0.000157	0.000232	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—SLC5A5—bile duct cancer	0.000153	0.000225	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—IDH1—bile duct cancer	0.000151	0.000222	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—NRAS—bile duct cancer	0.000151	0.000222	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—IL6—bile duct cancer	0.000151	0.000222	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TGFBR2—bile duct cancer	0.00015	0.000221	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—TGFB1—bile duct cancer	0.00015	0.000221	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—IDH1—bile duct cancer	0.00015	0.00022	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—IDH2—bile duct cancer	0.000149	0.000219	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—GNAS—bile duct cancer	0.000146	0.000215	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—GNAS—bile duct cancer	0.000146	0.000215	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—GNAS—bile duct cancer	0.000145	0.000213	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—EGFR—bile duct cancer	0.000144	0.000211	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—SMAD4—bile duct cancer	0.000142	0.000209	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.000141	0.000208	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—SLC5A5—bile duct cancer	0.000141	0.000207	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—TGFB1—bile duct cancer	0.00014	0.000206	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—KRAS—bile duct cancer	0.000139	0.000204	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TGFBR2—bile duct cancer	0.000137	0.000202	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TGFBR2—bile duct cancer	0.000136	0.0002	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—KRAS—bile duct cancer	0.000136	0.000199	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TGFBR2—bile duct cancer	0.000134	0.000197	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—SLC5A5—bile duct cancer	0.000132	0.000195	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—GNAS—bile duct cancer	0.000132	0.000194	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—GNAS—bile duct cancer	0.000131	0.000193	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—KRAS—bile duct cancer	0.00013	0.000191	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—SMAD4—bile duct cancer	0.00013	0.000191	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—GNAS—bile duct cancer	0.000129	0.00019	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—SMAD4—bile duct cancer	0.000129	0.000189	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—IDH1—bile duct cancer	0.000128	0.000188	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—SMAD4—bile duct cancer	0.000127	0.000187	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TGFBR2—bile duct cancer	0.000127	0.000187	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TGFBR2—bile duct cancer	0.000125	0.000184	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.000124	0.000183	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—TP53—bile duct cancer	0.000124	0.000182	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—NRAS—bile duct cancer	0.000123	0.00018	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—GNAS—bile duct cancer	0.000122	0.00018	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—ERBB2—bile duct cancer	0.000122	0.00018	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—ERBB2—bile duct cancer	0.000122	0.00018	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—GNAS—bile duct cancer	0.00012	0.000177	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—SMAD4—bile duct cancer	0.00012	0.000177	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—GNAS—bile duct cancer	0.000119	0.000175	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—SMAD4—bile duct cancer	0.000118	0.000174	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—HRAS—bile duct cancer	0.000118	0.000174	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—TP53—bile duct cancer	0.000115	0.00017	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—HRAS—bile duct cancer	0.000115	0.00017	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—IDH2—bile duct cancer	0.000115	0.000169	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TGFB1—bile duct cancer	0.000114	0.000167	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TGFBR2—bile duct cancer	0.000111	0.000163	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—HRAS—bile duct cancer	0.00011	0.000162	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—IL6—bile duct cancer	0.00011	0.000162	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—GNAS—bile duct cancer	0.000109	0.000161	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—GNAS—bile duct cancer	0.000107	0.000157	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—SLC5A5—bile duct cancer	0.000106	0.000156	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—KRAS—bile duct cancer	0.000105	0.000155	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—SMAD4—bile duct cancer	0.000105	0.000154	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MMP9—bile duct cancer	0.000105	0.000154	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MMP9—bile duct cancer	0.000105	0.000154	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TGFBR2—bile duct cancer	0.000103	0.000152	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—GNAS—bile duct cancer	0.000103	0.000151	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—NRAS—bile duct cancer	0.000103	0.000151	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—SLC5A5—bile duct cancer	9.97e-05	0.000147	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—GNAS—bile duct cancer	9.94e-05	0.000146	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—SLC5A5—bile duct cancer	9.88e-05	0.000145	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—IDH1—bile duct cancer	9.88e-05	0.000145	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—SMAD4—bile duct cancer	9.76e-05	0.000143	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TP53—bile duct cancer	9.37e-05	0.000138	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—NRAS—bile duct cancer	9.35e-05	0.000138	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—EGFR—bile duct cancer	9.35e-05	0.000138	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—NRAS—bile duct cancer	9.31e-05	0.000137	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—NRAS—bile duct cancer	9.29e-05	0.000137	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—NRAS—bile duct cancer	9.27e-05	0.000136	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	9.26e-05	0.000136	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—NRAS—bile duct cancer	9.15e-05	0.000135	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—HRAS—bile duct cancer	8.96e-05	0.000132	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—KRAS—bile duct cancer	8.84e-05	0.00013	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—NRAS—bile duct cancer	8.66e-05	0.000127	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TGFB1—bile duct cancer	8.65e-05	0.000127	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TGFB1—bile duct cancer	8.63e-05	0.000127	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—EGFR—bile duct cancer	8.52e-05	0.000125	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—NRAS—bile duct cancer	8.52e-05	0.000125	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—EGFR—bile duct cancer	8.48e-05	0.000125	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—EGFR—bile duct cancer	8.46e-05	0.000124	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—SLC5A5—bile duct cancer	8.45e-05	0.000124	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—EGFR—bile duct cancer	8.44e-05	0.000124	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—EGFR—bile duct cancer	8.34e-05	0.000123	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—GNAS—bile duct cancer	8.22e-05	0.000121	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—KRAS—bile duct cancer	8.05e-05	0.000118	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—KRAS—bile duct cancer	8.01e-05	0.000118	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—KRAS—bile duct cancer	8e-05	0.000118	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—KRAS—bile duct cancer	7.98e-05	0.000117	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—ERBB2—bile duct cancer	7.97e-05	0.000117	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	7.91e-05	0.000116	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—EGFR—bile duct cancer	7.89e-05	0.000116	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—KRAS—bile duct cancer	7.88e-05	0.000116	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—PTGS2—bile duct cancer	7.86e-05	0.000116	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—PTGS2—bile duct cancer	7.85e-05	0.000115	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—EGFR—bile duct cancer	7.76e-05	0.000114	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GNAS—bile duct cancer	7.75e-05	0.000114	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GNAS—bile duct cancer	7.68e-05	0.000113	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—NRAS—bile duct cancer	7.57e-05	0.000111	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—HRAS—bile duct cancer	7.51e-05	0.00011	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—KRAS—bile duct cancer	7.45e-05	0.00011	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—KRAS—bile duct cancer	7.33e-05	0.000108	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—ERBB2—bile duct cancer	7.26e-05	0.000107	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—ERBB2—bile duct cancer	7.2e-05	0.000106	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—IL6—bile duct cancer	7.19e-05	0.000106	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—bile duct cancer	7.12e-05	0.000105	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—bile duct cancer	7.11e-05	0.000104	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—ERBB2—bile duct cancer	7.11e-05	0.000104	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—NRAS—bile duct cancer	7.03e-05	0.000103	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—EGFR—bile duct cancer	6.9e-05	0.000101	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—HRAS—bile duct cancer	6.84e-05	0.000101	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MMP9—bile duct cancer	6.84e-05	0.000101	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—HRAS—bile duct cancer	6.81e-05	0.0001	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—HRAS—bile duct cancer	6.8e-05	9.99e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—HRAS—bile duct cancer	6.78e-05	9.97e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ERBB2—bile duct cancer	6.72e-05	9.88e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—HRAS—bile duct cancer	6.69e-05	9.84e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ERBB2—bile duct cancer	6.62e-05	9.73e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GNAS—bile duct cancer	6.56e-05	9.65e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—IL6—bile duct cancer	6.55e-05	9.63e-05	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IL6—bile duct cancer	6.52e-05	9.58e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—SLC5A5—bile duct cancer	6.52e-05	9.58e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—KRAS—bile duct cancer	6.51e-05	9.58e-05	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL6—bile duct cancer	6.5e-05	9.56e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL6—bile duct cancer	6.49e-05	9.54e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL6—bile duct cancer	6.41e-05	9.42e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—EGFR—bile duct cancer	6.41e-05	9.42e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—PTGS2—bile duct cancer	6.39e-05	9.39e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—HRAS—bile duct cancer	6.33e-05	9.31e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—HRAS—bile duct cancer	6.23e-05	9.17e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MMP9—bile duct cancer	6.23e-05	9.16e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MMP9—bile duct cancer	6.17e-05	9.08e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MMP9—bile duct cancer	6.09e-05	8.96e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NRAS—bile duct cancer	6.06e-05	8.92e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL6—bile duct cancer	6.06e-05	8.91e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—KRAS—bile duct cancer	6.05e-05	8.9e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL6—bile duct cancer	5.97e-05	8.77e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ERBB2—bile duct cancer	5.88e-05	8.64e-05	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—PTGS2—bile duct cancer	5.86e-05	8.62e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MMP9—bile duct cancer	5.77e-05	8.48e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MMP9—bile duct cancer	5.68e-05	8.34e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TGFB1—bile duct cancer	5.64e-05	8.29e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—HRAS—bile duct cancer	5.54e-05	8.14e-05	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—PTGS2—bile duct cancer	5.53e-05	8.13e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NRAS—bile duct cancer	5.53e-05	8.12e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—bile duct cancer	5.53e-05	8.12e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NRAS—bile duct cancer	5.48e-05	8.05e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ERBB2—bile duct cancer	5.46e-05	8.03e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NRAS—bile duct cancer	5.41e-05	7.95e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL6—bile duct cancer	5.3e-05	7.79e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KRAS—bile duct cancer	5.22e-05	7.67e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HRAS—bile duct cancer	5.14e-05	7.56e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TGFB1—bile duct cancer	5.13e-05	7.55e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NRAS—bile duct cancer	5.11e-05	7.52e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TGFB1—bile duct cancer	5.09e-05	7.48e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GNAS—bile duct cancer	5.07e-05	7.45e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MMP9—bile duct cancer	5.04e-05	7.41e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—bile duct cancer	5.03e-05	7.4e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NRAS—bile duct cancer	5.03e-05	7.4e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TGFB1—bile duct cancer	5.02e-05	7.39e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—bile duct cancer	4.99e-05	7.33e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—bile duct cancer	4.92e-05	7.24e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL6—bile duct cancer	4.92e-05	7.24e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KRAS—bile duct cancer	4.76e-05	6.99e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TGFB1—bile duct cancer	4.75e-05	6.99e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KRAS—bile duct cancer	4.71e-05	6.93e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MMP9—bile duct cancer	4.68e-05	6.89e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TGFB1—bile duct cancer	4.68e-05	6.88e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—bile duct cancer	4.66e-05	6.85e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KRAS—bile duct cancer	4.65e-05	6.84e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—bile duct cancer	4.64e-05	6.82e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—bile duct cancer	4.59e-05	6.74e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NRAS—bile duct cancer	4.47e-05	6.57e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HRAS—bile duct cancer	4.44e-05	6.52e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—PTGS2—bile duct cancer	4.42e-05	6.49e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KRAS—bile duct cancer	4.4e-05	6.47e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KRAS—bile duct cancer	4.33e-05	6.37e-05	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL6—bile duct cancer	4.25e-05	6.24e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—bile duct cancer	4.23e-05	6.22e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—bile duct cancer	4.19e-05	6.16e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—PTGS2—bile duct cancer	4.16e-05	6.12e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TGFB1—bile duct cancer	4.15e-05	6.11e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NRAS—bile duct cancer	4.15e-05	6.11e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—bile duct cancer	4.13e-05	6.08e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—PTGS2—bile duct cancer	4.12e-05	6.06e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—bile duct cancer	4.07e-05	5.99e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HRAS—bile duct cancer	4.04e-05	5.94e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HRAS—bile duct cancer	4.01e-05	5.89e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HRAS—bile duct cancer	3.95e-05	5.81e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—bile duct cancer	3.91e-05	5.75e-05	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL6—bile duct cancer	3.87e-05	5.69e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TGFB1—bile duct cancer	3.86e-05	5.68e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—bile duct cancer	3.85e-05	5.66e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KRAS—bile duct cancer	3.85e-05	5.66e-05	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL6—bile duct cancer	3.83e-05	5.64e-05	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL6—bile duct cancer	3.78e-05	5.56e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—bile duct cancer	3.78e-05	5.56e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HRAS—bile duct cancer	3.74e-05	5.5e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HRAS—bile duct cancer	3.68e-05	5.41e-05	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL6—bile duct cancer	3.58e-05	5.27e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KRAS—bile duct cancer	3.58e-05	5.26e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—PTGS2—bile duct cancer	3.52e-05	5.18e-05	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL6—bile duct cancer	3.52e-05	5.18e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—bile duct cancer	3.42e-05	5.03e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HRAS—bile duct cancer	3.27e-05	4.81e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—bile duct cancer	3.18e-05	4.67e-05	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL6—bile duct cancer	3.13e-05	4.6e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HRAS—bile duct cancer	3.04e-05	4.47e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL6—bile duct cancer	2.91e-05	4.28e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—PTGS2—bile duct cancer	2.72e-05	4e-05	CbGpPWpGaD
